LivaNova 2026 Stifel Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Rick Wise here, once again, and I am thrilled, truly thrilled to welcome Vlad Makatsaria, Chief Executive Officer of LivaNova, and Phil Kowalczyk, Chief Strategy and Corporate Development Officer. Vlad, I was reminding myself early this morning, in February, it is going to be three years since you got to LivaNova. I have just been reflecting what an amazing three years it has really been. Steady innovation cadence, top-notch operating performance, clearly more to come. You have annoyingly conservative guidance all the time that you insist on beating and exceeding. I think that is the way I was supposed to say it. But in each of your businesses, improved fundamentals, improved cadence of innovation ahead. It is an exciting time. You reported a terrific quarter.
So, just at a high level, starting us off, how sustainable We are going to get into the details, but at a high level, how sustainable is the kind of performance? Am I right in what I am saying?
Can it continue? First of all, thank you for the opportunity to join you today and for Thank you.
your advice and for your interest in LivaNova, and thank you everybody for joining this morning. Look, I mean, our philosophy is that we are, right now, we are pleased with our performance, but we are not satisfied. I think there is much more we can do moving forward, and I think this attitude of not getting complacent and keep driving the agenda of talent, of innovation, of execution, is at the forefront of what we do. In terms of sustainability, what I am really pleased with the trend that we are achieving, especially this year, is the quality of growth. And that growth, what I mean by that is, the growth is very well-balanced across different dimensions. Geographically, it is well-balanced across the world. It is now really well-balanced between the business units, so epilepsy is double-digit growth last quarter, and so was cardiopulmonary.
But even within each business unit, like if you look at cardiopulmonary, we were over-reliant on growth of HLMs, heart-lung machines. Now, oxygenators are growing double-digit. Heart-lung machines are growing double digits. If you look at epilepsy, price, volume, new patients, replacement, all kind of contributing to growth. And because of that high quality, our confidence in sustainability of growth is quite high.
Mm-hmm. Yeah. No, again, it seems like it should be. Let us dive right into the businesses. Cardiopulmonary capacity, innovation, and share gains. Talk about converting the now expanded oxygenator manufacturing capacity into sales. Your new line is operational. You are expecting double-digit output expansion in 2027. Is the opportunity primarily filling unmet demand? Is there unmet demand at existing accounts or increasing your share in those accounts or opening up new accounts? How do you have us think about each of those, and where is the best growth opportunity for you?
Yeah. So focusing on oxygenator, right?
Just oxygenator for now. I mean, I would start with the fact that the market growth has accelerated.
This was a low single-digit growth procedure market. Open heart surgery is growing at mid-single digits. From the demand point of view, it's getting higher. That's one dynamic. The other dynamic in the market that's worth pointing out, that one of the competitors, there were four companies that manufacture oxygenators that are main competitors, one out of them exited the market, that created additional opportunity for us. If I look at this business also, it's interesting because in this business, scale really matters. It's very high volume, relatively low value, and high capital intensity of portfolio. From that point of view, the bigger we get, I would say, the more tailwinds in the way we compete in the marketplace.
Over the last two years, we gained approximately 10 points of share. We went from 30 points to 40 points of share. We still operate in a situation where we have back orders. Everything we manufacture, we deliver to customers. Our strategy to continue gaining share is threefold. One is just commercial excellence, just, I think, basic commercial excellence. Number two is innovation, and I'm sure we'll talk about it, but in 2028, we're launching a new clinically differentiated oxygenator. Number three, it's improvements in our manufacturing and supply chain. The two big factors on supply chain came from our long-term partnership with Thermo Fisher, which gives us access to more critical components and kind of removes that as a governor of growth.
The big news internally is that recently we started manufacturing with our additional manufacturing line, that gives us, again, an opportunity to increase capacity by double digits in 2027.
You highlighted the new oxygenator as more efficient gas transfer, lower pressure drop, better platelet preservation. Our perfusionists and surgeons going to react to this? Do you have to show data? Is this a seamless, try our new one and they're going to light up and say, "Yes, this is what I want"?
Yeah, sure. As Vlad mentioned, that shift from 30% to 40% has really been driven by our investment in capacity. While there's still more runway there as we further invest in capacity in the Thermo deal, innovation will be the next phase of that growth in a way. It surprised me a little. I'd say when we first started and we meet with customers and say, "Where should innovation take place?" I had initial assumption that maybe oxygenators were a little more of a commodity. What we heard loud and clear from the clinical community is there is absolutely opportunity and value in innovation in oxygenators, and they were asking for it. Really, the balance in innovation in oxygenator is maintaining blood's contact with the fiber so you get that high-quality oxygenation, but in a way that doesn't damage the platelets.
From all the preclinical testing that we've done, we've created a design that across the 10 or so parameters that matter to a perfusionist, we are at par or better across every dimension. Historically, you were making some trade-offs between one or the other. We feel like we've really created a step change in innovation for the product, and the result is, we think, an opportunity to continue to drive not only in our current accounts, but also in competitive accounts as well. We're excited about that coming in 2028, and it's going to be an important innovation for our commercial organization to drive going forward.
It sounds compelling. On the HLM side, the heart-lung machine side, Essenz continues to be a success story, obviously. I think you recently highlighted that Essenz still is only 20% of your installed HLM base, so a lot more to go there. How much longer do you benefit from this upgrade cycle? When are you at 100%, and when does your oxygenator share catch up with your HLM share?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
